Cancer cells see the light
Nature Medicine
December 1, 2011
A method for selectively killing tumor cells — photoimmunotherapy — is reported in a study published online this week in Nature Medicine.
Surgery, radiation and chemotherapy are the mainstay of modern cancer therapy, but more targeted therapies aimed at specific molecules have been developed with some success.
Hisataka Kobayashi and his colleagues add photoimmunotherapy as a new weapon to the arsenal of targeted cancer therapy. This method uses anti-tumor antibodies coupled to a molecule that responds to near-infrared light. The authors found that when they shone near-infrared light on mice with tumors, the cancer cells selectively died.
Although other light-based therapies have been previously developed, Kobayashi and colleagues found one important difference — the modified antibody was not toxic unless it was attached to its target cells. This property may be critical if this technology is to have clinical potential.
doi: 10.1038/nm.2554
Research highlights
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports
-
Jun 24
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
Jun 23
Scientific community: Women credited less than men in scientific paper authorshipNature
-
Jun 17
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
Jun 17
Conservation: Feral cats pushing critically endangered marsupial further towards extinctionScientific Reports
-
Jun 16
Microbiology: DNA analysis indicates origins of the Black DeathNature